Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 6;8:600641. doi: 10.3389/fcell.2020.600641

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Yin, Tian, Yu, Yang, Su, Zhao, Wang, Zhang, Pei, Li, Chen, Zhang, Miao and Qian.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Rescue effect of miR-129-5p inhibitor on postmenopausal osteoporosis. (A) Representative images showing calvarial mineral apposition rate of C57BL/6 mice after OVX and inhibitor-129-5p treatment. Scale bar: 10 μm. BL (baseline): sacrifice before RNA treatment. Sham: sham OVX operation group. OVX: OVX group. Mock: transfection reagent control group. inhibit-NC: inhibitor-NC–treated group. inhibit-129: inhibitor-129-5p–treated group. (B) Calvarial mineral apposition rates of C57BL/6 mice after OVX and inhibitor-129-5p treatment (mean ± SD, ^∗∗∗P < 0.001). (C) Expression of OCN in calvarial tissues of C57BL/6 mice after OVX and inhibitor-129-5p treatment, as detected by immunohistochemical staining. Scale bar: 50 μm. (D) Quantification of relative integrated optical density (IOD) values of OCN immunostaining using Image-Pro Plus 6.0 software (mean ± SD, ^∗∗∗P < 0.001). (E) Expression of OXTERIX in calvarial tissues of C57BL/6 mice after OVX and inhibitor-129-5p treatment, as detected by immunohistochemical staining. Scale bar: 50 μm. (F) Quantification of relative IOD values of OXTERIX immunostaining using Image-Pro Plus 6.0 software (mean ± SD, ^∗∗∗P < 0.001). (G) Expression of RUNX2 in calvarial tissues of C57BL/6 mice after OVX and inhibitor-129-5p treatment, as detected by immunohistochemical staining. Scale bar: 50 μm. (H) Quantification of relative IOD values of RUNX2 immunostaining using Image-Pro Plus 6.0 software (mean ± SD, ^∗∗∗P < 0.001).